Daguindau et al. 1 recently described, in a cohort of 10 887 patients undergoing myeloablative allogeneic haematopoietic SCT (HSCT), 14 cases of autologous haematopoietic reconstitution, occurring in patients with leukaemia or myelodysplastic syndrome. Ten of these patients in fact never engrafted, and five of them ultimately relapsed. For the four patients who initially engrafted and subsequently lost the donor marrow, remission was still maintained. These results showed that loss of donor graft might not always be associated with disease relapse.
From 2000 to 2008, we treated 336 consecutive patients (192 men, 144 women) at a median age of 40 (18-58) years with myeloablative allogeneic HSCT. The underlying diagnoses included AML and myelodysplastic syndrome (n ¼ 158), ALL (n ¼ 68), myeloproliferative neoplasms (n ¼ 56), lymphomas (n ¼ 47) and plasma cell myeloma (n ¼ 7). Donor and recipient DNA were enumerated by a semi-quantitative PCR with fluorescence-labelled primers targeting polymorphic microsatellite loci. 2 In total, 1992 chimerism assessments were performed. Continued complete donor chimerism was documented in 218 cases, last assessed at a median of 45 (2-196) months post-HSCT. The haematological malignancies re-appeared in 17 patients with complete donor chimerism (myeloma, n ¼ 2; lymphoma, n ¼ 11; isolated extramedullary leukaemic relapse, n ¼ 3; donor-derived leukaemia, n ¼ 1). A mixed donor and recipient chimeric state (5-98% donor DNA) was found in 106 patients, all heralding disease relapse. A complete loss of donor chimerism occurred in the remaining 12 patients, with disease relapse occurring in 9 cases. Three patients, however, had sustained disease remission despite complete loss of donor chimerism ( Table 1) .
As these three patients were asymptomatic, the autologous regeneration was not evident clinically. Hence, occult autologous regeneration occurred with an overall frequency of 0.9% (3/336) after myeloablative allogeneic HSCT for haematological malignancies, and 6.4% (3/47) for lymphomas. In all three patients, the engraftment was smooth, with mild or no GVHD. Blood counts were normal, and immunosuppression was tapered off on schedule. Without chimerism analysis or other ancillary tests (blood groups 3 or glucose-6-phosphate dehydrogenase status 4 ), occult autologous regeneration would remain undiagnosed.
Another interesting observation was the rapid rate of autologous regeneration: 55-70% by 1 month (at engraftment) and 78-100% by 3 months. These results suggested that the conditioning regimen (cyclophosphamide, carmustine, etoposide) was not truly myeloablative. Instead, it is likely that to achieve complete donor chimerism at engraftment, in addition to high-dose chemotherapy, the incoming donor-derived immunocompetent cells also have an important role in suppressing residual recipient haematopoiesis.
As shown by Daguindau et al. and our data, chimerism analysis is of clinical significance after allogeneic HSCT. Early detection of complete loss of donor chimerism would allow cessation of unnecessary immunosuppression. Despite the high risks of relapse in our cases (disseminated and relapsed natural killer cell and aggressive T-cell and B-cell lymphomas), remission was maintained after autologous haematopoietic regeneration. There are several possible explanations. The high-dose conditioning chemotherapy may have destroyed residual lymphoma cells. A brief graftversus-lymphoma effect before loss of the allograft may Table 1 Autologous regeneration after myeloablative haematopoietic SCT for malignant lymphomas 
